Literature DB >> 25303419

Prevalence, awareness, treatment and control of hypertension in Henan Province, China.

Lei Fan1, Shi-xian Feng, Bing Han, Chong-chong Wang, Li Gao, Hua-feng Feng, Xiao-yan Qi, Gang Zhou.   

Abstract

OBJECTIVE: The present article aimed to explore and evaluate the epidemiology and determine the status of hypertension awareness, treatment and control in Henan province, China.
DESIGN: Cross-sectional survey.
SETTING: Thirty counties in Henan province of China. PARTICIPANTS: There were 18 772 randomly selected 15-74 years old. MAIN OUTCOME MEASURES: The distribution of blood pressure and prevalence, awareness, treatment and control of hypertension based on automated electronic monitor and questionnaire.
RESULTS: The crude prevalence of hypertension was 24.9%, and the standardised rate was 26.6%, meaning about 25 million were hypertensive in Henan province. Of which, 46% were aware of their hypertension diagnosis, 35.7% were having antihypertensive medicine, only 10.4% had their blood pressure controlled less than 140/90 mmHg, and 29.1% were being controlled when they were having antihypertensive medicine.
CONCLUSIONS: Hypertension is highly prevalent in Henan province, but the levels of hypertension awareness, treatment and control are low. Therefore, necessary actions including prevention, detection and treatment must be taken to keep the situation from worsening.
© 2014 National Rural Health Alliance Inc.

Entities:  

Keywords:  Henan; detection and control; hypertension epidemiology

Mesh:

Substances:

Year:  2014        PMID: 25303419     DOI: 10.1111/ajr.12116

Source DB:  PubMed          Journal:  Aust J Rural Health        ISSN: 1038-5282            Impact factor:   1.662


  7 in total

1.  Hypertension prevalence, awareness, treatment, and control in northeast China: a population-based cross-sectional survey.

Authors:  Fu-Liang Zhang; Zhen-Ni Guo; Ying-Qi Xing; Yan-Hua Wu; Hao-Yuan Liu; Yi Yang
Journal:  J Hum Hypertens       Date:  2017-11-27       Impact factor: 3.012

2.  Hypertension Prevalence, Awareness, Treatment, and Control in Selected LMIC Communities: Results From the NHLBI/UHG Network of Centers of Excellence for Chronic Diseases.

Authors:  Vilma E Irazola; Laura Gutierrez; Gerald Bloomfield; Rodrigo M Carrillo-Larco; Prabhakaran Dorairaj; Thomas Gaziano; Naomi S Levitt; J Jaime Miranda; Antonio Bernabe Ortiz; Krisela Steyn; Yangfeng Wu; Denis Xavier; Lijing L Yan; Jiang He; Adolfo Rubinstein
Journal:  Glob Heart       Date:  2016-03

3.  The Value of Four Anthropometric Indicators for Identifying Left Ventricular Hypertrophy in Chinese Hypertensive Patients.

Authors:  Bokai Cheng; Nan Lu; Ge Song; Jiaojiao Qiu; Jing Dong; Shuang Cai; Yongkang Su; Jin Sun; Anhang Zhang; Qiligeer Bao; Man Li; Shouyuan Ma; Yan Zhang; Ping Zhu; Shuxia Wang
Journal:  Int J Hypertens       Date:  2022-05-17       Impact factor: 2.434

4.  Epidemiological Characteristics of Hypertension in the Elderly in Beijing, China.

Authors:  Lina Ma; Xiaoling Zhao; Zhe Tang; Yun Li; Fei Sun; Lijun Diao; Gaizhen Ge; Ming Feng; Jieyu Wang
Journal:  PLoS One       Date:  2015-08-21       Impact factor: 3.240

5.  Prevalence, awareness, treatment, and control of hypertension and associated risk factors among adults in Xi'an, China: A cross-sectional study.

Authors:  Meiqin Hu; Yi Wan; Lifen Yu; Jing Yuan; Yonghong Ma; Bin Hou; Xun Jiang; Lei Shang
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

6.  Application of a Tabu search-based Bayesian network in identifying factors related to hypertension.

Authors:  Jinhua Pan; Huaxiang Rao; Xuelei Zhang; Wenhan Li; Zhen Wei; Zhuang Zhang; Hao Ren; Weimei Song; Yuying Hou; Lixia Qiu
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

Review 7.  Prevalence of Hypertension in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis.

Authors:  Ahmed M Sarki; Chidozie U Nduka; Saverio Stranges; Ngianga-Bakwin Kandala; Olalekan A Uthman
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.